United States RNAi for Therapeutic Market Report 2018

  • receipt Report ID : 26363
  • calendar_today Published On: Apr, 2018
  • file_copy Pages: 114
  • list Medical Devices
In this report, the United States RNAi for Therapeutic market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025.



Geographically, this report splits the United States market into seven regions:

The West

Southwest

The Middle Atlantic

New England

The South

The Midwest

with sales (volume), revenue (value), market share and growth rate of RNAi for Therapeutic in these regions, from 2013 to 2025 (forecast).



United States RNAi for Therapeutic market competition by top manufacturers/players, with RNAi for Therapeutic sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including

Alnylam Pharmaceuticals

Arbutus Biopharma (Tekmira)

Arrowhead Research

Dicerna Pharmaceuticals

Mirna Therapeutics

Quark Pharmaceuticals

RXi Pharmaceuticals

Silence Therapeutics

Benitec Biopharma

Miragen Therapeutics

Sylentis

Gradalis

Sirnaomics

Silenseed

Arcturus Therapeutics

Ariz Biopharma

Celsion Corporation

Ascletis Pharmaceuticals



On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

siRNA

miRNA

shRNA

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

Cancer

Cardiovascular

HBV

Other



If you have any special requirements, please let us know and we will offer you the report as you want.



Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

Table of Contents



United States RNAi for Therapeutic Market Report 2018

1 RNAi for Therapeutic Overview

1.1 Product Overview and Scope of RNAi for Therapeutic

1.2 Classification of RNAi for Therapeutic by Product Category

1.2.1 United States RNAi for Therapeutic Market Size (Sales Volume) Comparison by Type (2013-2025)

1.2.2 United States RNAi for Therapeutic Market Size (Sales Volume) Market Share by Type (Product Category) in 2017

1.2.3 siRNA

1.2.4 miRNA

1.2.5 shRNA

1.3 United States RNAi for Therapeutic Market by Application/End Users

1.3.1 United States RNAi for Therapeutic Market Size (Consumption) and Market Share Comparison by Application (2013-2025)

1.3.2 Cancer

1.3.3 Cardiovascular

1.3.4 HBV

1.3.5 Other

1.4 United States RNAi for Therapeutic Market by Region

1.4.1 United States RNAi for Therapeutic Market Size (Value) Comparison by Region (2013-2025)

1.4.2 The West RNAi for Therapeutic Status and Prospect (2013-2025)

1.4.3 Southwest RNAi for Therapeutic Status and Prospect (2013-2025)

1.4.4 The Middle Atlantic RNAi for Therapeutic Status and Prospect (2013-2025)

1.4.5 New England RNAi for Therapeutic Status and Prospect (2013-2025)

1.4.6 The South RNAi for Therapeutic Status and Prospect (2013-2025)

1.4.7 The Midwest RNAi for Therapeutic Status and Prospect (2013-2025)

1.5 United States Market Size (Value and Volume) of RNAi for Therapeutic (2013-2025)

1.5.1 United States RNAi for Therapeutic Sales and Growth Rate (2013-2025)

1.5.2 United States RNAi for Therapeutic Revenue and Growth Rate (2013-2025)



2 United States RNAi for Therapeutic Market Competition by Players/Suppliers

2.1 United States RNAi for Therapeutic Sales and Market Share of Key Players/Suppliers (2013-2018)

2.2 United States RNAi for Therapeutic Revenue and Share by Players/Suppliers (2013-2018)

2.3 United States RNAi for Therapeutic Average Price by Players/Suppliers (2013-2018)

2.4 United States RNAi for Therapeutic Market Competitive Situation and Trends

2.4.1 United States RNAi for Therapeutic Market Concentration Rate

2.4.2 United States RNAi for Therapeutic Market Share of Top 3 and Top 5 Players/Suppliers

2.4.3 Mergers & Acquisitions, Expansion in United States Market

2.5 United States Players/Suppliers RNAi for Therapeutic Manufacturing Base Distribution, Sales Area, Product Type



3 United States RNAi for Therapeutic Sales (Volume) and Revenue (Value) by Region (2013-2018)

3.1 United States RNAi for Therapeutic Sales and Market Share by Region (2013-2018)

3.2 United States RNAi for Therapeutic Revenue and Market Share by Region (2013-2018)

3.3 United States RNAi for Therapeutic Price by Region (2013-2018)



4 United States RNAi for Therapeutic Sales (Volume) and Revenue (Value) by Type (Product Category) (2013-2018)

4.1 United States RNAi for Therapeutic Sales and Market Share by Type (Product Category) (2013-2018)

4.2 United States RNAi for Therapeutic Revenue and Market Share by Type (2013-2018)

4.3 United States RNAi for Therapeutic Price by Type (2013-2018)

4.4 United States RNAi for Therapeutic Sales Growth Rate by Type (2013-2018)



5 United States RNAi for Therapeutic Sales (Volume) by Application (2013-2018)

5.1 United States RNAi for Therapeutic Sales and Market Share by Application (2013-2018)

5.2 United States RNAi for Therapeutic Sales Growth Rate by Application (2013-2018)

5.3 Market Drivers and Opportunities



6 United States RNAi for Therapeutic Players/Suppliers Profiles and Sales Data

6.1 Alnylam Pharmaceuticals

6.1.1 Company Basic Information, Manufacturing Base and Competitors

6.1.2 RNAi for Therapeutic Product Category, Application and Specification

6.1.2.1 Product A

6.1.2.2 Product B

6.1.3 Alnylam Pharmaceuticals RNAi for Therapeutic Sales, Revenue, Price and Gross Margin (2013-2018)

6.1.4 Main Business/Business Overview

6.2 Arbutus Biopharma (Tekmira)

6.2.2 RNAi for Therapeutic Product Category, Application and Specification

6.2.2.1 Product A

6.2.2.2 Product B

6.2.3 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Sales, Revenue, Price and Gross Margin (2013-2018)

6.2.4 Main Business/Business Overview

6.3 Arrowhead Research

6.3.2 RNAi for Therapeutic Product Category, Application and Specification

6.3.2.1 Product A

6.3.2.2 Product B

6.3.3 Arrowhead Research RNAi for Therapeutic Sales, Revenue, Price and Gross Margin (2013-2018)

6.3.4 Main Business/Business Overview

6.4 Dicerna Pharmaceuticals

6.4.2 RNAi for Therapeutic Product Category, Application and Specification

6.4.2.1 Product A

6.4.2.2 Product B

6.4.3 Dicerna Pharmaceuticals RNAi for Therapeutic Sales, Revenue, Price and Gross Margin (2013-2018)

6.4.4 Main Business/Business Overview

6.5 Mirna Therapeutics

6.5.2 RNAi for Therapeutic Product Category, Application and Specification

6.5.2.1 Product A

6.5.2.2 Product B

6.5.3 Mirna Therapeutics RNAi for Therapeutic Sales, Revenue, Price and Gross Margin (2013-2018)

6.5.4 Main Business/Business Overview

6.6 Quark Pharmaceuticals

6.6.2 RNAi for Therapeutic Product Category, Application and Specification

6.6.2.1 Product A

6.6.2.2 Product B

6.6.3 Quark Pharmaceuticals RNAi for Therapeutic Sales, Revenue, Price and Gross Margin (2013-2018)

6.6.4 Main Business/Business Overview

6.7 RXi Pharmaceuticals

6.7.2 RNAi for Therapeutic Product Category, Application and Specification

6.7.2.1 Product A

6.7.2.2 Product B

6.7.3 RXi Pharmaceuticals RNAi for Therapeutic Sales, Revenue, Price and Gross Margin (2013-2018)

6.7.4 Main Business/Business Overview

6.8 Silence Therapeutics

6.8.2 RNAi for Therapeutic Product Category, Application and Specification

6.8.2.1 Product A

6.8.2.2 Product B

6.8.3 Silence Therapeutics RNAi for Therapeutic Sales, Revenue, Price and Gross Margin (2013-2018)

6.8.4 Main Business/Business Overview

6.9 Benitec Biopharma

6.9.2 RNAi for Therapeutic Product Category, Application and Specification

6.9.2.1 Product A

6.9.2.2 Product B

6.9.3 Benitec Biopharma RNAi for Therapeutic Sales, Revenue, Price and Gross Margin (2013-2018)

6.9.4 Main Business/Business Overview

6.10 Miragen Therapeutics

6.10.2 RNAi for Therapeutic Product Category, Application and Specification

6.10.2.1 Product A

6.10.2.2 Product B

6.10.3 Miragen Therapeutics RNAi for Therapeutic Sales, Revenue, Price and Gross Margin (2013-2018)

6.10.4 Main Business/Business Overview

6.11 Sylentis

6.12 Gradalis

6.13 Sirnaomics

6.14 Silenseed

6.15 Arcturus Therapeutics

6.16 Ariz Biopharma

6.17 Celsion Corporation

6.18 Ascletis Pharmaceuticals



7 RNAi for Therapeutic Manufacturing Cost Analysis

7.1 RNAi for Therapeutic Key Raw Materials Analysis

7.1.1 Key Raw Materials

7.1.2 Price Trend of Key Raw Materials

7.1.3 Key Suppliers of Raw Materials

7.1.4 Market Concentration Rate of Raw Materials

7.2 Proportion of Manufacturing Cost Structure

7.2.1 Raw Materials

7.2.2 Labor Cost

7.2.3 Manufacturing Expenses

7.3 Manufacturing Process Analysis of RNAi for Therapeutic



8 Industrial Chain, Sourcing Strategy and Downstream Buyers

8.1 RNAi for Therapeutic Industrial Chain Analysis

8.2 Upstream Raw Materials Sourcing

8.3 Raw Materials Sources of RNAi for Therapeutic Major Manufacturers in 2017

8.4 Downstream Buyers



9 Marketing Strategy Analysis, Distributors/Traders

9.1 Marketing Channel

9.1.1 Direct Marketing

9.1.2 Indirect Marketing

9.1.3 Marketing Channel Development Trend

9.2 Market Positioning

9.2.1 Pricing Strategy

9.2.2 Brand Strategy

9.2.3 Target Client

9.3 Distributors/Traders List



10 Market Effect Factors Analysis

10.1 Technology Progress/Risk

10.1.1 Substitutes Threat

10.1.2 Technology Progress in Related Industry

10.2 Consumer Needs/Customer Preference Change

10.3 Economic/Political Environmental Change



11 United States RNAi for Therapeutic Market Size (Value and Volume) Forecast (2018-2025)

11.1 United States RNAi for Therapeutic Sales Volume, Revenue Forecast (2018-2025)

11.2 United States RNAi for Therapeutic Sales Volume Forecast by Type (2018-2025)

11.3 United States RNAi for Therapeutic Sales Volume Forecast by Application (2018-2025)

11.4 United States RNAi for Therapeutic Sales Volume Forecast by Region (2018-2025)



12 Research Findings and Conclusion



13 Appendix

13.1 Methodology/Research Approach

13.1.1 Research Programs/Design

13.1.2 Market Size Estimation

13.1.3 Market Breakdown and Data Triangulation

13.2 Data Source

13.2.1 Secondary Sources

13.2.2 Primary Sources

13.3 Disclaimer





1

Please fill the form below, to recieve the report sample


+1